Evidence map›Paper›PMID 29904611›Full record

ArticleBiomedical reports2018

Urinary diagnostic proteomic markers for dynapenia in cancer patients.

Holger Husi, Alisdair MacDonald, Richard J E Skipworth, Janice Miller, Andrew Cronshaw, Carolyn Greig, Kenneth C H Fearon, James A Ross

Open access · diamondAbstract read
In one paragraph

Article in Biomedical reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Holger HusiDepartment of Diabetes and Cardiovascular Science, University of the Highlands and Islands, Centre for Health Science, IV2 3JH Inverness, UK.
Alisdair MacDonaldSchool of Clinical Sciences, University of Edinburgh, EH16 4SB Edinburgh, UK.
Richard J E SkipworthSchool of Clinical Sciences, University of Edinburgh, EH16 4SB Edinburgh, UK.
Janice MillerSchool of Clinical Sciences, University of Edinburgh, EH16 4SB Edinburgh, UK.
Andrew CronshawSchool of Biological Sciences, University of Edinburgh, EH16 4SB Edinburgh, UK.
Carolyn GreigSchool of Clinical Sciences, University of Edinburgh, EH16 4SB Edinburgh, UK.
Kenneth C H FearonSchool of Clinical Sciences, University of Edinburgh, EH16 4SB Edinburgh, UK.
James A RossSchool of Clinical Sciences, University of Edinburgh, EH16 4SB Edinburgh, UK.
University of Edinburgh · GBUniversity of the Highlands and Islands · GB

Funding

Medical Research Council MR/K00414X/1
6 · The paper itself

Abstract

Dynapenia is defined as the age-related loss of muscle strength, and plays a significant role in the loss of physical function and increased risk of disability among older individuals. The need for an early diagnosis supports the search for a biomarker that reflects muscle 'weakening'. This has previously proven difficult due to patient heterogeneity at presentation and lack of understanding of the underlying molecular mechanisms. The aim of the present study was to identify potential urinary biomarkers of dynapenia in patients undergoing potentially curative surgery for upper gastrointestinal cancer. Maximum isometric knee extensor strength (strain gauge) and maximum leg extensor power (Nottingham power rig) measurements were taken. Cut-off values for dynapenia were based on the Allied Dunbar national fitness survey. Values below the 5th percentile for the population matched for age and sex on the Allied Dunbar national fitness survey were used to stratify the cohort into dynapenic or normal. Urine samples taken at induction of anaesthesia were analysed by SELDI-TOF mass spectrometry using CM10 and IMAC30 chip-types to establish statistically significant m/z peak fingerprint patterns, followed by in-gel LC-MS/MS to identify molecular constituents. Statistical analysis of decision-tree calculations using Biomarker Pattern software resulted in models with sensitivities of 86 and 96%, specificities of 81 and 89%, and overall correctness of 84 and 93%, when applied to the entire cohort for power and strength measurement-based stratifications using the IMAC30 chip-type and the CM10 chip-type, respectively. The molecular identities of 10 peaks of interest were further investigated. After subtraction of potentially unrelated proteins, they were identified as fragments of Annexin A1, collagen α-1 (XV), perlecan and myotrophin. These results demonstrate that urinary screening can be used to define cancer-associated muscle weakness, and the identification of potential biomarkers could be invaluable in establishing a rapid test to measure and assess dynapenia in the clinical setting.

Indexed as

dynapeniamuscle wastingSELDI-TOFurine biomarker

Identifiers

PMID29904611
PMCPMC5996844
OpenAlexW2799447834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.